TransCode Therapeutics announces retirement of CEO

TransCode Therapeutics ( NASDAQ: RNAZ ) on Friday announced the retirement of co founder and Chief Executive Officer, Michael Dudley. Tom Fitzgerald, currently Chief Financial Officer and a director of TransCode, will become interim CEO. Dudley will resign as an executive officer and director of the company effective January 13, 2024.

TransCode’s Board also elevated Zdravka Medarova, currently Chief Technology Officer, to the role of Chief Scientific Officer. Philippe Calais, currently Chairman of the Board of Directors, will assume the position of Executive Chairman, the company said. Source: Press Release More on TransCode Therapeutics TransCode Therapeutics announces $1.2M registered direct offering of common stock TransCode shares plunge 20% on stock offering, Nasdaq compliance update Seeking Alpha’s Quant Rating on TransCode Therapeutics.